Non-Muscle – Talk Bio

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

3 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer

3 months ago talkbio0Tagged BCG Vaccine, Blocker, Carcinoma of urinary bladder, invasive, Keytruda, Malignant neoplasm of urinary bladder, Non-Muscle, PDCD1 gene, Pfizer, Phase 3 trial, Sasanlimab

Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda

Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes

5 months ago talkbio0Tagged Carcinoma of urinary bladder, invasive, Cell Therapy, centigram, Cretostimogene Grenadenorepvec, Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant Neoplasms, Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Oncolytic Immunotherapy, Protara Therapeutics, Urinary Bladder

Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy